Verastem, Inc.
VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 20ā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.87
Price-0.76%
-$0.06
1Y
Price
Market Cap
$476.438m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-873.7%
EBITDA Margin-876.3%
Net Profit Margin-322.1%
Free Cash Flow MarginRevenue
$13.379m
+33.8%
1y CAGR-22.1%
3y CAGR-9.9%
5y CAGREarnings
-$241.106m
-84.6%
1y CAGR-50.8%
3y CAGR-39.0%
5y CAGREPS
-$4.63
-26.5%
1y CAGR-1.9%
3y CAGR+0.4%
5y CAGRBook Value
-$15.526m
$176.852m
Assets$192.378m
Liabilities$89.477m
DebtDebt to Assets
50.6%
-0.4x
Debt to EBITDAFree Cash Flow
-$132.654m
-26.6%
1y CAGR-27.9%
3y CAGR-25.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company